NCT07750665尚未招募2 期
A Study to Evaluate the Long-term Efficacy and Safety of FXS6837 in IgAN Patients
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年9月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events
研究概览
简要总结
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have completed the study treatment in FXS6837-IIb-201, and are evaluated by the investigator to have an anticipated benefit exceeding risk with long-term FXS6837 treatment;
- •eGFR (CKD-EPI) ≥ 30 mL/min/1.73 m2 at screening;
- •Vaccinated against Neisseria meningitidis and Streptococcus pneumoniae as required by the previous study (Booster vaccination should be administered promptly in accordance with vaccination guidelines and local immunization authority requirements if the vaccine protection period fails to cover the treatment duration of this study);
- •Able to continue optimized treatment with RASi, SGLT2i, ERA, and hydroxychloroquine throughout the study with stable prescribed dosing;
- •Have a detailed understanding of the nature, significance, possible benefits, potential inconveniences, and potential risks of the trial, and voluntarily participate in this clinical trial; Able to communicate well with the investigators and comply with the requirements of the entire study; And signed a written ICF;
- •Participants of reproductive potential commit to having no plans for pregnancy or sperm/egg donation from screening until 1 month (female participants) or 3 months (male participants) after the last dose and voluntarily take effective physical contraceptive methods (including partners).
排除标准
- •Known or suspected by investigators to have immunodeficiency diseases or hereditary complement deficiency;
- •Any organ transplant recipients (except corneal transplant);
- •Concomitant major systemic diseases, including but not limited to: advanced heart disease (such as NYHA class IV), severe pulmonary disease (such as severe pulmonary hypertension [WHO class IV]), active hepatitis, or other major systemic diseases assessed by investigators as unable to participate in this study;
- •History of malignant tumors within 5 years before screening (except carcinoma in situ and thyroid cancer assessed by investigators as curatively resected).
- •5. Previous history of Neisseria meningitidis or recurrent Streptococcus pneumoniae infection ;
- •Suspected or known history of allergies to similar ingredients of the study drug or any ingredient in the study drug;
- •Pregnant or lactating women or those with positive pregnancy test results;
- •Other conditions deemed by the investigator that may potentially interfere with study conduct, impose additional risks to the participant, or render the individual ineligible for study participation.
研究组 & 干预措施
experimental:FXS6837
Experimental
FXS6837 Capsule
干预措施: FXS6837 Capsule (Drug)
结局指标
主要结局
Incidence and severity of adverse events
时间窗: through study completion, an average of 2 years
次要结局
- Ratio of urine albumin-to-creatinine ratio (UACR) to baseline at each visit(through study completion, an average of 2 years)
- Ratio of 24-h urine protein (24 hour-UPE) to baseline at each visit(through study completion, an average of 2 years)
- Ratio of urine protein-to-creatinine ratio (UPCR) to baseline at each visit(through study completion, an average of 2 years)
- Ratio of 24-h urine albumin excretion (24 hour-UAE) to baseline at each visit(through study completion, an average of 2 years)
- Change from baseline in estimated glomerular filtration rate (eGFR) at each visit(through study completion, an average of 2 years)
- Trough plasma concentration of FXS6837(through study completion, an average of 2 years)
- Complement AP activity in peripheral blood at each visit point(through study completion, an average of 2 years)
- Levels and changes of PD biomarkers in plasma and urine at each visit(through study completion, an average of 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07657052S-INFINITY Pharmaceuticals Co., Ltd26
招募中
2 期
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseNCT07399704Azafaros B.V.21
Enrolling By Invitation
3 期
Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaFibromyalgiaNCT07637162Axsome Therapeutics, Inc.300
已完成
3 期
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease2024-511553-22-00Celgene International II SARL462
招募中
3 期
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 1015550CTRI/2024/10/075029Boehringer Ingelheim17